Upfront Fees for Preclinical-Stage Biotech Products
Upfront fees for preclinical stage products in 1994-95 are bigger than those from deals signed in 91-93.
You may also be interested in...
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.
The deal is part of Medtronic's ongoing strategy to revive its diabetes business with technology that simplifies insulin delivery.
In advisory committee briefing documents, agency also says critical quality attributes of the graft-versus-host disease treatment do not show a relationship with clinical potency and may not ensure control of clinical effectiveness of individual drug product lots.